Effect of chemotherapy on quality of life in patients with non-small cell lung cancer

Supportive Care in Cancer

Volumn 22, Issue 5, 2014, Pages 1417-1428

  Mannion, Eileen ^a   Gilmartin, J J ^a   Donnellan, Paul ^a   Keane, MacCon ^a   Waldron, Dympna ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Non small cell lung cancer; Palliative chemotherapy; Quality of life

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; TENIPOSIDE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; DOSAGE SCHEDULE COMPARISON; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER-QUALITY OF LIFE QUESTIONNAIRE; EXPECTATION; FUNCTIONAL ASSESSMENT OF CANCER THERAPY-LUNG; FUNCTIONAL LIVING INDEX CANCER SCALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LUNG CANCER SYMPTOM SCALE; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH COUNCIL DAILY DIARY CARD; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; ROTTERDAM SYMPTOM CHECKLIST; SHORT TERM SURVIVAL; SICKNESS IMPACT PROFILE; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897521948     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2148-9     Document Type: Review

References (116)

1. Aaronson NK (1992) Assessing the quality of life of patients in cancer clinical trials. Common problems and common sense solutions. Eur J Cancer 28A:1304-1307
2. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15:744-749 (Pubitemid 27074244)
3. Akerly W, Glantz M, Choy H et al (1998) Phase II trial of weekly paclitaxel in advanced non-small cell lung cancer. J Clin Oncol 16: 153-158 (Pubitemid 28041593)
4. Anderson H, Hopwood P, Stephens RJ et al (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 83:447-453 (Pubitemid 30487855)
5. Baka S, Ashcroft L, AndersonMet al (2005) Randomized phase III study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status <70) and advanced non-small-cell lung cancer. J Clin Oncol 23:2136-2144 (Pubitemid 46218705)
6. Belani CP, Pereira JR, von Pawel J et al (2006) Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer 53:231-239 (Pubitemid 44043122)
7. Bergman B, Aaronson NK, Ahmedazi S et al (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A:635-642 (Pubitemid 24164250)
8. Bergner M, Bobbitt RA, Carter WB et al (1981) The Sickness Impact Profile: development and final revision of a health status measure. Med Care 19:787-805 (Pubitemid 11021288)
9. Bonomi P, KyungMann K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-672
10. Borgstrom P, Gold DP, Hillian KJ et al (1999) Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEG neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19: 4203-4214
11. Bowling A (1991) A Review of Quality of Life Measurement Scales. Meas Health, Open University Press, Milton Keynes
12. Bowling A (1995) A Review of Disease-Specific Quality of Life Measurement Scales. Meas Health, Open University Press, Milton Keynes
13. Breathnach OS, Freidlin B, Conley B et al (2001) Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1734-1742 (Pubitemid 32230875)
14. Brown J, Thorpe H, Napp Vet al (2005) Assessment of quality of life in the supportive care setting of The Big Lung Trial in non-small-cell lung cancer. J Clin Oncol 23:7417-7427 (Pubitemid 46291803)
15. Buccheri GF, Ferrigno D, Curcia A et al (1989) Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer 63:428-432 (Pubitemid 19038453)
16. Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review. Clin Cancer Res 5:1087-1100
17. Calman KC (1984) Quality of life in cancer patients: an hypothesis. J Med Ethics 10:124-127
18. Cardenal F, Lopez-Cabrerizo MP, AntonAet al (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non small cell lung cancer. J Clin Oncol 17:12-18 (Pubitemid 29022372)
19. Carney DN, Hansen HH (2000) Non-small-cell lung cancer - stalemate or progress. N Engl J Med 343:1261-1262
20. Cella DF, Bonomi AE, Lloyd SR et al (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220
21. Cella D, Herbst RS, Lynch TJ et al (2005) Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23:2946-2954 (Pubitemid 46224113)
22. Crino L, Scagliotti GV, Ricci S et al (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non small cell lung cancer: a randomised phase III study of the Italian Lung Cancer Project. J Clin Oncol 17:3522-3530 (Pubitemid 29517923)
23. CullenMH, Billingham LJ,Woodroffe CM et al (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17(10):3188-3194 (Pubitemid 29470650)
24. Dancey J, Shepherd FA, Gralla RJ et al (2004) Quality of life assessment of second line docetaxel versus best supportive care in patients with non small cell lung cancer previously treated with platinum based chemotherapy: results of a prospective, randomised phase III trial. Lung Cancer 43:183-194 (Pubitemid 38114747)
25. de Haes JC, van Knippenburg FC, Neijit JP (1990) Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62:1034-1038
26. Emmanuel LL, Barry MJ, Stoeckle JD et al (1991) Advance directives for medical care: a case for greater use. N Engl J Med 324:889-895
27. Fairclough DL (1997) Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 16:1197-1209
28. Fayers PM, Jones DR (1983) Measuring and analysing quality of life in cancer clinical trials: a review. Stat Med 2:429-446 (Pubitemid 14145327)
29. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676 (Pubitemid 36749215)
30. Fidias PM, Dakhil SR, Lyss AP et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 27:591-598
31. Frasci G, Lorusso V, Panza N et al (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non small cell lung cancer. J Clin Oncol 18:2529-2536 (Pubitemid 30432518)
32. Fujino S, Enokibori T, Tezuka N et al (1996) A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small-cell lung cancer. Eur J Cancer 32A:2070-2074 (Pubitemid 26419455)
33. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21:2237-2246 (Pubitemid 46621858)
34. Gatzemeier U, von Pawel J, Gottfried M et al (2000) Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390-3399
35. Gebbia V, Lorusso V, Galetta D et al (2010) First line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Lung Cancer 69:218-224
36. Georgoulias V, Papadakis E, Alexopoulos A et al (2001) Platinum-based and non-platinum-based chemotherapy in advanced nonsmall cell lung cancer: a randomized multicentre trial. Lancet 357: 1478-1484 (Pubitemid 32488857)
37. Georgoulias V, Ardavanis A, Tsiafaki X et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23: 2937-2945 (Pubitemid 46224112)
38. Giaccone G, Splinter TA, Debruyne C et al (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16:2133-2141 (Pubitemid 28265050)
39. Gill TM, Feinstein AR (1994) A critical appraisal of the quality of quality of life measurements. JAMA 272:619-626 (Pubitemid 24255222)
40. Greenlee RT, Hill-Harmon MB, Murray T, Thun T (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15-36 (Pubitemid 32166444)
41. Gridelli C, Gallo C, Shepherd FA et al (2003) Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer. J Clin Oncol 21:3025-3034
42. Gridelli C, Gallo C, Di Maio M et al (2004) A randomised clinical trial of two docetaxel regimens (weekly versus 3 week) in the second-line treatment of non-small-cell lung cancer: the DISTAL 01 study. Br J Cancer 91:1996-2004 (Pubitemid 40128765)
43. Gridelli C, Kaukel E, Gregorc V et al (2007) Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2:221-229 (Pubitemid 47181327)
44. Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11(10):1866-1872 (Pubitemid 23304609)
45. Gronberg BH, Bremnes RM, Flotten O et al (2009) Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as firstline chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217-3224
46. Hanna N, Shepherd FA, Fossella FVet al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597 (Pubitemid 41079796)
47. Helsing M, Bergman B, Thaning L et al (1998) Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 34(7):1036-1044 (Pubitemid 28308344)
48. Herndon JE, Fleishman S, Kosty MP et al (1997) A longitudinal study of quality of life in advanced non-small-cell lung cancer: Cancer and Leukaemia Group B (CALGB) 8931. Control Clin Trials 18:286-300 (Pubitemid 27337018)
49. Hollen PJ, Gralla RJ (1996) Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 23(suppl 5):31-40 (Pubitemid 26130113)
50. Hollen PJ, Gralla RJ, Kriss MG et al (1993) Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A(suppl 1):S51-58 (Pubitemid 23021152)
51. Joyce CRB (1994) Health status and quality of life: which matters to the patient? J Cardiovasc Pharmacol 23(suppl 3):26-33
52. Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer. A Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218 (Pubitemid 32591438)
53. Kim KJ, Li B,Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844 (Pubitemid 23132159)
54. Kosmidis P, Mylonakis N, Nicolaides C et al (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced nonsmall cell lung cancer: a phase III randomized trial. J Clin Oncol 20:3578-3585 (Pubitemid 34983216)
55. Kubota K, Watanabe K, Kunitoh H et al (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254-261 (Pubitemid 41095089)
56. Laack E, Dickgreber N, Muller Tet al (2004) Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22:2348-2356 (Pubitemid 41115391)
57. Langer CJ, Leighton JC, Comis RL et al (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 13:1860-1870
58. Langer CJ, Manolo J, Bernardo P et al (2002) Cisplatin based therapy for elderly patients with advanced NSCLC: implications of Eastern Co-operative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181 (Pubitemid 34162751)
59. Le Chevalier T, Pujol JL, Douillard JY et al (1994) A three arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin Oncol 21:28-33
60. Leplege A, Hunt S (1997) The problem of quality of life in medicine. JAMA 278:47-50 (Pubitemid 27274516)
61. Lillenbaum RC, Chen CS, Chidiac T et al (2005) Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 16:97-101
62. Ma CX, Nair S, Thomas S et al (2005) Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front line therapy for advanced non-small-cell lung cancer. J Clin Oncol 25:5929-5937
63. Manegold G, Bergman B, Chemaissani A et al (1997) Single agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 8:525-529 (Pubitemid 127746483)
64. Marino P, Pampallona S, Preatoni A et al (1994) Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest 106(3):861-865 (Pubitemid 24278896)
65. Maruyama R, Nishiwaki Y, Tamura T et al (2008) Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 26:4244-4252
66. Moinpour CM, Lyons B, Grevstad PK et al (2002) Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomised trial. Qual Life Res 11:115-126 (Pubitemid 34438158)
67. Mok T,Wu Y, Thongprasert S et al (2009) Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-57
68. Montazeri A, Gillis CR,McEwen J (1998) Quality of life in patients with lung cancer: a review of literature from 1970-1995. Chest 113: 467-81 (Pubitemid 28110027)
69. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311(7010):899-909
70. O'Boyle CA (1994) The schedule for the evaluation of individual quality of life. Int J Ment Health 23:3-23
71. O'Boyle CA, Waldron D (1997) Quality of life issues in palliative medicine. J Neurol 224(suppl 4):18-25
72. Olschewski M, Schulgen G, Schumacher M et al (1994) Quality of life assessment in clinical cancer research. Br J Cancer 70:1-5 (Pubitemid 24203619)
73. Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12:608-616
74. Osoba D (1996) Quality of life assessment in palliative medicine. Prog Palliat Care 4:167-168, editorial
75. Paccagnella A, Favaretto A, Oniga F et al (2004) Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 43:83-91 (Pubitemid 38096297)
76. Parkin DM, Pisani P, Ferlay J (1993) Estimation of the worldwide incidence of 18 major cancers in 1985. Int J Cancer 54: 594-606 (Pubitemid 23188190)
77. Patrick DL, Erickson P (1993) Assessing health-related quality of life for clinical decision-making. In: Walker SR, Rosser RM (eds) Quality of life assessment: key issues for the 1990s. Kluwer Academic, London, pp 11-64
78. Patrick DL, Erickson P (1993) Health status and health policy: allocating resources to health care. Oxford University Press, New York, pp 3-26
79. Pavelic K, Banjac Z, Pavelic J et al (1993) Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13:1133-1137 (Pubitemid 23247476)
80. Perng RP, Chen YM, Ming-Liu J et al (1997) Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15:2097-2102 (Pubitemid 27209542)
81. Presant CA (1984) Quality of life in cancer patients: who measures what? Am J Clin Oncol 7:571-573
82. RansonM, Davidson N, Nicholson M et al (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92: 1074-1080 (Pubitemid 30616481)
83. Richards T (1998) Partnership with patients. BMJ 316:85-86, editorial
84. Rosell R, Gatzmeier U, Betticher DC et al (2002) Phase III randomized trial comparing paclitaxel / carboplatin with paclitaxel / cisplatin in patients with advanced non small cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539-1549 (Pubitemid 35331451)
85. Roszkowski K, Pluzanska A, Krzakowski M et al (2000) Multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27:145-157 (Pubitemid 30105654)
86. Rudd RM, Gower NH, Spiro SG et al (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23: 142-153 (Pubitemid 41702633)
87. Sandler A, Ettinger DS (1999) Gemcitabine; Single agent and combination therapy in non-small cell lung cancer. Oncologist 4: 241-251
88. Sandler AB, Ansari R, McClean J et al (1995) Gemcitabine plus cisplatin in non-small cell lung cancer: a phase II study. Eur J Cancer 31 A(suppl 5):S225
89. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
90. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98 (Pubitemid 34438899)
91. Schipper H, Clinch J, McMurray A et al (1984) Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 2:472-483 (Pubitemid 14075981)
92. Schuette W, Nagel S, Blakenburg T et al (2005) Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23: 8389-8395
93. Sederholm C, Hillerdal G, Lamberg K et al (2005) Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 23: 8380-8388
94. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 19:2095-2103 (Pubitemid 30324363)
95. Shepherd FA, Dancey J, Arnold A et al (2001) Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92:595-600 (Pubitemid 32735195)
96. Shepherd FA, Rodrigues PJ, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132 (Pubitemid 41058344)
97. Silvestri G, Pritchard R, Welch G (1998) Preferences for chemotherapy in patients with advanced NSCLC: descriptive study based on scripted interviews. BMJ 317:771-775 (Pubitemid 28427226)
98. Slevin ML, Plant H, Lynch D et al (1988) Who should measure quality of life, the doctor or the patient? Br J Cancer 57:109-112 (Pubitemid 18067115)
99. Smit EF, van Meerbeeck PAM, Lianes P et al (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel and gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Group-EORTC 08975. J Clin Oncol 21:3909-3917 (Pubitemid 46606203)
100. Smith IE, O'Brien MER, Talbot DC et al (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol 19:1336-1343 (Pubitemid 32202538)
101. Socinski MA, Schell MJ, Peterman A et al (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335-1343 (Pubitemid 34182817)
102. Souquet PJ, Chauvin F, Boissel JP et al (1993) Polychemotherapy in advanced non small cell lung cancer: a meta analysis. Lancet 342(8862):19-22
103. Spilker B (ed) (1996) Quality of life and pharmacoeconomics in clinical trials (ed 2). Raven, New York, pp 1-10
104. Spiro SG, Rudd RM, Souhami RL et al (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59: 828-836 (Pubitemid 39389621)
105. Spitzer WO, Dobson AJ, Hall J et al (1981) Measuring quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34:585-597 (Pubitemid 12237535)
106. Temel J, Greer J, MuzikanskyA et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733-742
107. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537 (Pubitemid 41540110)
108. The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72
109. Thongprasert S, Sanguanmitra P, Juthapan W et al (1999) Relationship between quality of life and clinical outcomes in advanced non-small-cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24(1):17-24 (Pubitemid 29241813)
110. Vansteenkiste J, Vandebroek J, Nackaerts K et al (2001) Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomized phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12:1221-1230 (Pubitemid 32994749)
111. Varricchio CG, McCabe MS, Trimble E et al (1996) Quality of life in cancer clinical trials. J Natl Cancer Inst Monogr 20:vii-viii
112. Volm M, Rittgen W, Drings P (1998) Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77:663-669 (Pubitemid 28059477)
113. von Plessen C, Bergman B, Andresen O et al (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality of life benefits in advanced non-small-cell lung cancer. Br J Cancer 95:966-973 (Pubitemid 44606820)
114. Waldron D, O' Boyle CA (1998) Individual quality of life in palliative care. In: Joyce CRB, O 'Boyle CA, McGee H (eds) Individual quality of life approaches to conceptualisation and assessment in health. Harwood Academic, Reading, pp 197-211
115. Waldron DW, O'Boyle CA, Kearney ML et al (1999) Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol 17:3603-3611 (Pubitemid 29517933)
116. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370 (Pubitemid 13098606)